Pinnacle Associates LTD Vertex Pharmaceuticals Inc Transaction History

Pinnacle Associates LTD

$6.3 Billion
Q3 2024

A detailed history of Pinnacle Associates LTD transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Pinnacle Associates LTD holds 6,039 shares of VRTX stock, worth $3.12 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

6,039

Previous 10,861 44.4%

Holding current value

$3.12 Million

Previous $5.09 Million 44.83%

% of portfolio

0.04%

Previous 0.08%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 25, 2024	SELL	$460.0 - $505.78 $2.22 Million - $2.44 Million	-4,822 Reduced 44.4%	6,039 $2.81 Million
Q2 2024 Jul 30, 2024	BUY	$392.81 - $485.53 $680,346 - $840,937	1,732 Added 18.97%	10,861 $5.09 Million
Q1 2024 Apr 26, 2024	BUY	$407.69 - $446.08 $1.26 Million - $1.38 Million	3,090 Added 51.17%	9,129 $3.82 Million
Q4 2023 Jan 19, 2024	BUY	$343.0 - $410.68 $267,540 - $320,330	780 Added 14.83%	6,039 $2.46 Million
Q3 2023 Oct 23, 2023	BUY	$338.18 - $362.46 $517,753 - $554,926	1,531 Added 41.07%	5,259 $1.83 Million
Q2 2023 Jul 26, 2023	BUY	$314.42 - $351.91 $580,419 - $649,625	1,846 Added 98.09%	3,728 $1.31 Million
Q1 2023 May 04, 2023	BUY	$283.23 - $323.1 $113,292 - $129,240	400 Added 26.99%	1,882 $592,000
Q4 2022 Jan 31, 2023	SELL	$285.76 - $321.48 $22,575 - $25,396	-79 Reduced 5.06%	1,482 $427,000
Q4 2022 Jan 25, 2023	SELL	$285.76 - $321.48 $28,861 - $32,469	-101 Reduced 6.08%	1,561 $0
Q3 2022 Oct 31, 2022	BUY	$273.83 - $305.53 $43,538 - $48,579	159 Added 10.58%	1,662 $481,000
Q2 2022 Aug 02, 2022	BUY	$234.96 - $292.55 $65,788 - $81,914	280 Added 22.89%	1,503 $424,000
Q1 2022 May 05, 2022	BUY	$221.42 - $260.97 $4,428 - $5,219	20 Added 1.66%	1,223 $319,000
Q4 2021 Feb 02, 2022	SELL	$177.01 - $223.45 $38,234 - $48,265	-216 Reduced 15.22%	1,203 $264,000
Q3 2021 Oct 19, 2021	SELL	$181.39 - $202.99 $36,278 - $40,598	-200 Reduced 12.35%	1,419 $257,000
Q2 2021 Aug 02, 2021	BUY	$187.49 - $221.1 $74,996 - $88,440	400 Added 32.81%	1,619 $326,000
Q1 2021 May 12, 2021	BUY	$207.02 - $241.31 $41,404 - $48,262	200 Added 19.63%	1,219 $262,000
Q4 2020 Jan 26, 2021	BUY	$207.01 - $276.09 $19,872 - $26,504	96 Added 10.4%	1,019 $241,000
Q3 2020 Oct 23, 2020	BUY	$255.65 - $303.1 $1,022 - $1,212	4 Added 0.44%	923 $251,000
Q2 2020 Aug 14, 2020	SELL	$225.48 - $295.8 $45,096 - $59,160	-200 Reduced 17.87%	919 $267,000
Q4 2019 Feb 03, 2020	BUY	$166.71 - $223.91 $186,548 - $250,555	1,119 New	1,119 $245,000
Q3 2019 Nov 08, 2019	SELL	$166.23 - $187.09 $182,853 - $205,799	-1,100 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$163.73 - $194.7 $180,103 - $214,170	1,100 New	1,100 $202,000
Q4 2018 Feb 05, 2019	SELL	$151.91 - $192.21 $182,292 - $230,652	-1,200 Closed	0 $0
Q2 2018 Aug 08, 2018	BUY	$145.72 - $169.96 $174,864 - $203,952	1,200 New	1,200 $204,000
Q3 2017 Nov 13, 2017	SELL	$148.13 - $162.24 $318,331 - $348,653	-2,149 Closed	0 $0
Q2 2017 Aug 09, 2017	BUY	N/A	2,149	2,149 $277,000

Others Institutions Holding VRTX

# of Institutions

1,717

Shares Held

226M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $133B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pinnacle Associates LTD, based on Form 13F filings with the SEC.

News

Stay updated on Pinnacle Associates LTD with notifications on news.

Account

Pinnacle Associates LTD Vertex Pharmaceuticals Inc Transaction History